Spots Global Cancer Trial Database for tumor lysis syndrome
Every month we try and update this database with for tumor lysis syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | NCT04745910 | Hematopoietic a... Malignant Solid... Tumor Lysis Syn... | Pegloticase Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | NCT03098589 | Lymphoma | Revlimid | 18 Years - | Celgene | |
| Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome | NCT00230178 | Tumor Lysis Syn... Cancer Hyperuricemia | Rasburicase (SR... Allopurinol | 18 Years - | Sanofi | |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies | NCT01724528 | Tumor Lysis Syn... | Febuxostat Allopurinol | 18 Years - | Menarini Group | |
| Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma | NCT00445341 | Lymphoma | Flavopiridol | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy | NCT00230217 | Tumors Hyperuricemia Tumor Lysis Syn... | Rasburicase (SR... | - | Sanofi | |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | NCT03406156 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab Bendamustine Venetoclax | 18 Years - 99 Years | AbbVie | |
| Rasburicase in Patients at Risk for Tumor Lysis Syndrome | NCT00628628 | Tumor Lysis Syn... | As Needed Rasbu... Fixed Dose Rasb... | - | M.D. Anderson Cancer Center | |
| A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma | NCT05840289 | Aggressive B-Ce... | fractionated fi... | - | University Hospital, Geneva | |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | NCT04214093 | Advanced Solid ... Lymphoma Multiple Myelom... Hematologic Mal... | AZD0466 | 18 Years - 130 Years | AstraZeneca | |
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS | NCT00360438 | Leukemia Lymphoma Tumor Lysis Syn... | Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS | NCT00360438 | Leukemia Lymphoma Tumor Lysis Syn... | Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Fasturtec TLS Treatment / Prophylysis | NCT00651911 | Tumor Lysis Syn... | urate oxidase | 18 Years - | Sanofi | |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults | NCT03605212 | Tumor Lysis Syn... | Febuxostat | 6 Years - | Menarini Group | |
| Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients | NCT00186940 | Leukemia Lymphoma Tumor Lysis Syn... Hyperuricemia | Rasburicase | - | St. Jude Children's Research Hospital | |
| Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients | NCT00186940 | Leukemia Lymphoma Tumor Lysis Syn... Hyperuricemia | Rasburicase | - | St. Jude Children's Research Hospital | |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors | NCT04214093 | Advanced Solid ... Lymphoma Multiple Myelom... Hematologic Mal... | AZD0466 | 18 Years - 130 Years | AstraZeneca | |
| Elitek (Rasburicase) Immuno-Monitoring Study | NCT01097369 | Tumor Lysis Syn... | 2 Years - | Sanofi | ||
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS | NCT00360438 | Leukemia Lymphoma Tumor Lysis Syn... | Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma | NCT05840289 | Aggressive B-Ce... | fractionated fi... | - | University Hospital, Geneva | |
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | NCT03098589 | Lymphoma | Revlimid | 18 Years - | Celgene | |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies | NCT01724528 | Tumor Lysis Syn... | Febuxostat Allopurinol | 18 Years - | Menarini Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
